shutterstock-135807482-roche-1
lucarista / shutterstock.com
20 May 2021Big PharmaAlex Baldwin

Roche subsidiary sues Bluebird over ‘Spark’ TM

Roche Group’s subsidiary  Spark Therapeutics has filed a complaint against rival gene therapy company  Bluebird Bio, accusing it of infringing its ‘Spark’ trademark.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
14 April 2021   Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.
Americas
3 May 2017   GSK and biotech company Bluebird Bio have entered into a licence agreement centring on Bluebird’s lentiviral vector platform.

More on this story

Big Pharma
14 April 2021   Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.
Americas
3 May 2017   GSK and biotech company Bluebird Bio have entered into a licence agreement centring on Bluebird’s lentiviral vector platform.

More on this story

Big Pharma
14 April 2021   Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.
Americas
3 May 2017   GSK and biotech company Bluebird Bio have entered into a licence agreement centring on Bluebird’s lentiviral vector platform.